The Perrigo Company has entered into a purchase agreement to acquire nine generic prescription dermatological products and four pipeline products from Glades Pharmaceuticals, Inc. for $56 million in cash plus other consideration for future R&D collaborations. The transaction is expected to close by the end of March. Perrigo president and chief executive officer, Joe Papa, stated, “We have enhanced our existing U.S. product portfolio and future pipeline with this strategic acquisi...